|
Affiliation |
Faculty of Medicine School of Medicine Department of Medicine of Sensory and Motor Organs, Dermatology |
|
Title |
Professor |
|
Related SDGs |
|
OGATA Dai
|
|
|
Papers 【 display / non-display 】
-
Watanabe T, Omura G, Mori T, Yoshimoto S, Ogata D
Auris, nasus, larynx 2026.8
Language：English Publishing type：Research paper (scientific journal) Publisher：Auris Nasus Larynx
Immune checkpoint inhibitor (ICI) therapy may be accompanied by immune-related adverse events (irAEs). Severe irAEs frequently require immunosuppressive treatment with high-dose corticosteroids and, in refractory cases, additional agents such as infliximab. Under these circumstances, patients may become susceptible to opportunistic infections, including cytomegalovirus (CMV), which can present with clinical features closely resembling irAEs. We report the case of a 79-year-old man with malignant melanoma of the sphenoid sinus who was treated using nivolumab and ipilimumab. He developed immune-related colitis, requiring corticosteroid and infliximab treatment. Subsequently, he presented with severe pharyngeal pain and extensive oral and pharyngeal mucosal erosions, which were initially suspected to represent irAE-related mucositis. However, the lesions did not improve despite corticosteroid re-escalation. CMV antigenemia increased over time, and biopsy of the buccal mucosa confirmed CMV mucositis by immunohistochemistry. Intravenous ganciclovir led to marked clinical and virological improvement, allowing resumption of oral intake. Therefore, CMV mucositis can mimic an irAE during ICI therapy, and the risk of opportunistic infection in this setting arises primarily from immunosuppressive treatment for irAEs rather than from ICIs themselves. When severe mucosal lesions are persistent or refractory to corticosteroid escalation, clinicians should consider opportunistic infections and pursue prompt tissue evaluation for definitive diagnosis.
-
Komori T, Nakano E, Kiniwa Y, Mori S, Yamamoto S, Kato H, Yoshikawa S, Yoshino K, Aoki M, Takenouchi T, Maeda T, Yoshino K, Ohe S, Nakama K, Ishikawa H, Nakamura Y, Takai T, Ito T, Kitagawa H, Kokubu H, Hatta N, Funakoshi T, Hoashi T, Suyama T, Fujiwara S, Masuzawa M, Uchi H, Miyagawa T, Kado S, Yamamoto Y, Asai J, Kato J, Maeda T, Baba N, Kato Y, Oashi K, Maekawa T, Jinnai S, Nishizawa A, Kagoyama K, Otsuka A, Nishihara K, Ogata D, Namikawa K, Nakamura Y, Matsushita S
The Journal of dermatology 53 ( 8 ) 1124 - 1132 2026.8
Language：English Publishing type：Research paper (scientific journal) Publisher：Journal of Dermatology
Nail apparatus melanoma (NAM) is a biologically and clinically distinct subtype of melanoma; however, the efficacy of adjuvant interferon (IFN) therapy in this population remains unclear. We conducted a multicenter retrospective study to compare adjuvant IFN-β (adj-IFN) with observation (OBS) in patients with resected stage IIB, IIC, or III NAM. We analyzed 282 Japanese patients treated at 42 institutions between 2014 and 2024. Recurrence–free survival (RFS) and distant metastasis–free survival (DMFS) were co-primary outcomes, and overall survival (OS) was a secondary outcome. Survival outcomes were assessed using Kaplan–Meier analyses and Cox multivariable proportional hazards models. To minimize the differences of baseline characteristics between the two groups, propensity score matching (PSM) was applied. In multivariable Cox analyses, adj-IFN showed improved RFS (HR 0.67, 95% CI 0.45–0.998, p = 0.049), while no statistically significant benefits were observed for DMFS (HR 0.66, 95% CI 0.42–1.01, p = 0.06) or OS (HR 0.85, 95% CI 0.54–1.35, p = 0.50) compared with OBS. After PSM (71 patients per group), survival outcomes were comparable between the two groups, with no statistical significance in RFS (HR 0.71, 95% CI 0.45–1.12, p = 0.14), DMFS (HR 0.73, 95% CI 0.44–1.20, p = 0.22), or OS (HR 1.01, 95% CI 0.58–1.78, p = 0.96). In conclusion, no significant survival advantage of adj-IFN over observation was demonstrated in the matched cohort. Although a borderline association with improved RFS was observed in the overall cohort, this finding did not translate into consistent benefit across endpoints. Further prospective evidence, including the final results of the randomized phase III trial (JCOG1309, J-FERON), is required to clarify the clinical role of adj-IFN in NAM.
-
皮心伝心 出会いを大切に Reviewed
緒方 大
皮膚病診療 48 ( 7 ) 627 - 627 2026.7
Publishing type：Research paper (scientific journal) Publisher：協和企画
-
巻頭言 おかれた場所で咲く Reviewed
緒方 大
皮膚科の臨床 68 ( 4 ) 393 - 394 2026.4
Publishing type：Research paper (scientific journal) Publisher：金原出版
-
Efficacy and safety of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma in Japan: Results of the Japan Clinical Oncology Group single-arm confirmatory trial (JCOG1605). Reviewed
Oashi K, Ogata D, Yokoyama M, Sano Y, Fukuda H, Hiura A, Nakamura Y, Uehara J, Takahashi A, Namikawa K, Mori S, Nakano E, Maeda T, Miyagawa T, Yoshino K, Funakoshi T, Kiniwa Y, Nakagawa T, Shibayama Y, Uchi H, Maeda T, Muto I, Maruyama A, Takenouchi T, Hatta N, Yamazaki N
The British journal of dermatology 2026.3
Language：English Publishing type：Research paper (scientific journal)
DOI： 10.1093/bjd/ljag071
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
神経皮膚症候群および色素性乾皮症・ポルフィリン症の学際的診療体制に基づく医療 最適化と患者 QOL 向上のための研究
Grant number：23FC1037 2023.04 - 2026.03
厚生労働省 厚生科研 難治性疾患政策研究事業
Authorship：Coinvestigator(s)
-
悪性黒色腫におけるALDH2遺伝子多型の発症と予後に関する影響の解明
Grant number：21K16218 2021.04 - 2027.03
独立行政法人日本学術振興会 科学研究費基金 若手研究
Authorship：Principal investigator